ArticleGates open research2026
Geospatial Settlement Data and Immunization Reach in Polio SIAs: Evidence from Axis of Intractable Transmission States in Northern Nigeria.
Article in Gates open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The persistent transmission of circulating vaccine-derived poliovirus type 2 (cVDPV2) in Northern Nigeria, especially in the Axis of Intractable Transmission (AIT) states, Kebbi, Sokoto, Katsina, and Zamfara, despite national certification of wild poliovirus interruption, is strongly associated with fragmented settlement visibility, population denominator inaccuracies, and uneven implementation of Supplementary Immunization Activities (SIAs). This study examines whether these geospatial investments as broader ecosystem of interventions improve immunization reach and operational quality during cVDPV2 SIAs. Methods: A retrospective operational analysis was conducted using data from nine consecutive SIAs (April 2024-June 2025). We extracted state-level indicators from the Master List of Settlements (MLoS) geospatial records and campaign data, which included (1) geospatial completeness, defined as the proportion of settlements with validated coordinates; (2) settlement tracking coverage; (3) MLoS-derived population targets for children; and (4) number of children vaccinated. Descriptive statistics, bivariate exploratory relationships, and temporal learning analysis were performed to evaluate how geospatial status influenced tracking outcomes. Results: Geospatial completeness ranged from 92.1% (Zamfara) to 100% (Kebbi) and was associated with higher, more stable tracking coverage. Kebbi, with complete geolocation of settlements, demonstrated consistently strong tracking performance (mean 93%). Settlement tracking correlated positively with vaccination outputs in Kebbi and Sokoto but demonstrated saturation effects in Katsina and diminishing returns in Zamfara. Operational learning was observed in Sokoto, Katsina, and Zamfara, each demonstrating 8 to 10 percentage point improvements in tracking coverage across rounds. Conclusion: In addition to other contributory factors, settlement-level geolocation improves the quality and reach of cVDPV2 SIAs by strengthening visibility of target populations and promoting more reliable tracking. The MLoS updates and tracking of settlements and vaccination teams demonstrated transformative potential in optimizing vaccination campaigns by improving equity, accountability, and efficiency. Its deployment offers valuable lessons for enhancing immunization efforts in resource-constrained and security-compromised settings, emphasizing the importance of strategic integration and sustained investments in public health innovation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.